Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women

To prevent the global health burdens of human immunodeficiency virus [HIV] and unintended/mistimed pregnancies, we developed an intravaginal ring [IVR] that delivers tenofovir [TFV] at ~10mg/day alone or with levonorgestrel [LNG] at ~20μg/day for 90 days. We present safety, pharmacokinetics, pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Thurman, Andrea Ries, Schwartz, Jill L., Brache, Vivian, Clark, Meredith R., McCormick, Timothy, Chandra, Neelima, Marzinke, Mark A., Stanczyk, Frank Z., Dezzutti, Charlene S., Hillier, Sharon L., Herold, Betsy C., Fichorova, Raina, Asin, Susana N., Rollenhagen, Christiane, Weiner, Debra, Kiser, Patrick, Doncel, Gustavo F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023238/
https://www.ncbi.nlm.nih.gov/pubmed/29953547
http://dx.doi.org/10.1371/journal.pone.0199778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023238/
https://www.ncbi.nlm.nih.gov/pubmed/29953547
http://dx.doi.org/10.1371/journal.pone.0199778

Ejemplares similares